- Home
- SCNX vs VYNE Comparison
SCNX vs VYNE Comparison
Compare SCNX & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCNX | VYNE |
|---|---|---|
| Founded | 2010 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4M | 20.0M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | SCNX | VYNE |
|---|---|---|
| Price | $0.39 | $0.59 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | 266.6K | ★ 323.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $347.88 | N/A |
| Revenue Next Year | $744.44 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.29 |
| 52 Week High | $3.17 | $2.05 |
Technical Indicators
Market Signals| Indicator | SCNX | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 39.14 | 54.69 |
| Support Level | $0.37 | $0.55 |
| Resistance Level | $0.47 | $0.60 |
| Average True Range (ATR) | 0.03 | 0.02 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 17.42 | 56.07 |
Price Performance
Historical ComparisonAbout SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.